secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-09-25T20:05:28+00:00
Accession:  0001178913-26-004604
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4.1-flash:cloud@v2

Silexion shareholders reject 175M-share capital increase and 1-for-15 reverse split
--------------------------------------------------------------------------------

- Proposal 1 to increase authorized capital by 175,000,000 ordinary shares, to US$25,771,500 divided into 190,900,000 shares, failed: 24.6% in favor, 75.4% against, 27,003 abstentions.
- Proposal 2 to authorize a 1-for-15 reverse share split of all issued, outstanding and unissued ordinary shares failed: 25.9% in favor, 74.1% against.
- Neither proposal received a simple majority of shareholders present, so neither was approved at the reconvened extraordinary general meeting.
- Meeting originally scheduled September 9, 2026, adjourned twice for lack of quorum, then reconvened September 23, 2026 with 2,208,353 shares (about 36.8% of issued and outstanding) present.
- After a half hour without a quorum, the shareholders present constituted a quorum under Article 21.3 of the amended and restated articles of association.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004604/0001178913-26-004604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004604/zk2636155.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer